The FDA accepts Sarepta's (SRPT) regulatory filing seeking accelerated approval for SRP-9001, a gene therapy for DMD indication. A final decision is expected by May 2023.
Sarepta's (SRPT) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales. Shares decline in after-market trading post the announcement.
Earlier today, we released our financial results for the third quarter of 2022. Joining us on the call today are Doug Ingram, Ian Estepan, Dallan Murray and Dr. After our formal remarks, we'll open the call for Q&A. I'd like to note that during this call, we will be making a number of forward-looking statements.